Evogene

EVGN

Market cap $9.15M

Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design and patient-derived predictive platform REHOVOT, Israel and BOSTON, January 7, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform.

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

EverGen Infrastructure Corp. ( EVGN:CA ) Q3 2025 Earnings Call November 21, 2025 11:00 AM EST Company Participants Chase Edgelow - CEO & Director Maria O'Sullivan - Interim Chief Financial Officer Presentation Operator Welcome to the EverGen Infrastructure Third Quarter 2025 earnings results presentation. [Operator Instructions] As a reminder, this call is being recorded.

Evogene Ltd. ( EVGN ) Q3 2025 Earnings Call November 20, 2025 9:00 AM EST Company Participants Ofer Haviv - CEO, President & Director Yaron Eldad - Chief Financial Officer Presentation Operator Welcome to Evogene's Third Quarter 2025 Results Conference Call.

Conference call and webcast: today, November 20, 2025, 9:00 AM ET Financial Highlights: During the first nine months ending September 30, 2025, Evogene advanced its strategic transition toward establishing itself as a leader in computational chemistry, with a focus on the generative design of small molecules for the pharmaceutical and agricultural industries. As part of this new strategy, the company executed an organizational realignment and cost-reduction plan, most of which was completed by the end of the second quarter.

Collaboration focuses on integrating high-yield castor varieties with advanced mechanized solutions, including harvesting and threshing technologies REHOVOT, Israel and MANTOVA, Italy , Nov. 11, 2025 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), an Israeli developer of high-yield castor seed varieties and integrated castor farming solutions — and a subsidiary of Evogene Ltd.

Zoom conference call scheduled for November 20, 2025, 9:00 AM ET REHOVOT, Israel , Nov. 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter of 2025, on Thursday , November 20 , 2025.

REHOVOT, Israel , Aug. 28, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company, today announced that Ofer Haviv, Evogene's President and CEO, will present at the H.C.

Evogene Ltd. (NASDAQ:EVGN ) Q2 2025 Earnings Conference Call August 19, 2025 9:00 AM ET Company Participants Ofer Haviv - CEO, President & Director Yaron Eldad - Chief Financial Officer Unidentified Company Representative Welcome to Evogene's Second Quarter 2025 Results Conference Call.

Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net".